387 related articles for article (PubMed ID: 19176441)
21. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
22. NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease.
Sullivan EM; Jeha S; Kang G; Cheng C; Rooney B; Holladay M; Bari R; Schell S; Tuggle M; Pui CH; Leung W
Clin Cancer Res; 2014 Dec; 20(23):5986-94. PubMed ID: 25281696
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
25. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
28. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients.
Wesołowska-Andersen A; Borst L; Dalgaard MD; Yadav R; Rasmussen KK; Wehner PS; Rasmussen M; Ørntoft TF; Nordentoft I; Koehler R; Bartram CR; Schrappe M; Sicheritz-Ponten T; Gautier L; Marquart H; Madsen HO; Brunak S; Stanulla M; Gupta R; Schmiegelow K
Leukemia; 2015 Feb; 29(2):297-303. PubMed ID: 24990611
[TBL] [Abstract][Full Text] [Related]
30. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.
Xu XJ; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
Leuk Res; 2012 Aug; 36(8):1022-7. PubMed ID: 22483330
[TBL] [Abstract][Full Text] [Related]
31. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Coustan-Smith E; Gajjar A; Hijiya N; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Andreansky M; Hancock ML; Pui CH; Campana D
Leukemia; 2004 Mar; 18(3):499-504. PubMed ID: 14981525
[TBL] [Abstract][Full Text] [Related]
33. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
Gabor KM; Schermann G; Lautner-Csorba O; Rarosi F; Erdelyi DJ; Endreffy E; Berek K; Bartyik K; Bereczki C; Szalai C; Semsei AF
Pediatr Blood Cancer; 2015 Apr; 62(4):622-8. PubMed ID: 25557962
[TBL] [Abstract][Full Text] [Related]
34. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
36. [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
Pawińska-Wasikowska K; Balwierz W
Przegl Lek; 2010; 67(6):361-5. PubMed ID: 21344762
[TBL] [Abstract][Full Text] [Related]
37. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse.
Jacquy C; Delepaut B; Van Daele S; Vaerman JL; Zenebergh A; Brichard B; Vermylen C; Cornu G; Martiat P
Br J Haematol; 1997 Jul; 98(1):140-6. PubMed ID: 9233577
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
39. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]